Literature DB >> 7690699

Characterization of 2',3'-dideoxycytidine diphosphocholine and 2',3'-dideoxycytidine diphosphoethanolamine. Prominent phosphodiester metabolites of the anti-HIV nucleoside 2',3'-dideoxycytidine.

Z Hao1, E E Stowe, G Ahluwalia, D C Baker, A K Hebbler, C Chisena, S M Musser, J A Kelley, C F Perno, D G Johns.   

Abstract

2',3'-Dideoxycytidine (ddCyd) is among the most potent of the anti-human immunodeficiency virus (HIV) agents of the dideoxynucleoside class. Its pharmacologically active metabolite 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) is an effective inhibitor of HIV reverse transcriptase and thus of HIV replication. ddCyd differs, however, from other dideoxynucleoside agents such as 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in its capacity to generate phosphodiester metabolites (i.e. ddCDP choline and ddCDP ethanolamine). We have synthesized and characterized these two diesters, and established their identity with the metabolites formed in ddCyd-treated Molt-4 cells. Toward this end, the biologically generated metabolites have been isolated on a preparative scale and compared with the synthetic compounds mass spectroscopically, chromatographically, and enzymatically (i.e. their relative susceptibility to the catabolic enzymes alkaline phosphatase and venom phosphodiesterase). The concentration reached by each of these two phosphodiesters within cells can, under certain conditions, equal or exceed that of ddCTP, and their half-times of disappearance are long, indicating that they may serve as depot forms of ddCyd. The possible role of these phosphodiesters in contributing to the unusual toxicity of ddCyd is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690699

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.

Authors:  Brenda I Hernandez-Santiago; Judy S Mathew; Kim L Rapp; Jason P Grier; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

2.  Metabolism, mitochondrial uptake and toxicity of 2', 3'-dideoxycytidine.

Authors:  L Rossi; S Serafini; G F Schiavano; A Casabianca; G Vallanti; L Chiarantini; M Magnani
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

3.  Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys.

Authors:  Brenda I Hernandez-Santiago; Huachun Chen; Ghazia Asif; Thierry Beltran; Shuli Mao; Selwyn J Hurwitz; Jason Grier; Harold M McClure; Chung K Chu; Dennis C Liotta; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 4.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.

Authors:  M T Paff; D R Averett; K L Prus; W H Miller; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.

Authors:  W Y Gao; D G Johns; S Chokekuchai; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

7.  2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line.

Authors:  M Magnani; G Brandi; A Casabianca; A Fraternale; G F Schiavano; L Rossi; L Chiarantini
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.